Updated:
Methuselah Foundation
Founded in 2003 by British gerontologist Aubrey de Grey and American entrepreneur David Gobel, the Methuselah Foundation operates as a 501(c)(3) nonprofit...
Methuselah Foundation
Founded in 2003 by British gerontologist Aubrey de Grey and American entrepreneur David Gobel, the Methuselah Foundation operates as a 501(c)(3) nonprofit with the stated goal of extending the human healthspan. The name references the biblical figure Methuselah, who lived to 969 years, metaphorically representing the drive to end age-related disease. The organization is headquartered in Palo Alto but maintains offices in San Francisco, Leipzig, Graz, Hingham, and Schwyz, reflecting a broad geographic footprint. The foundation's strategy centers on the SENS (Strategies for Engineered Negligible Senescence) framework, which identifies seven categories of age-related damage and proposes repair-based interventions. Direct program investments target biotechnology — including stem cell therapies, mitochondrial repair, and telomere elongation — with public positions in companies such as AgeX Therapeutics (per public filings) and follow-on ventures via its spinout, the Longevity Fund. Geographically, the foundation funds research globally, spanning the US and Europe, with the MAIA fund vehicle accelerating preclinical innovations. Aubrey de Grey remains Chief Science Officer, overseeing scientific direction, while David Gobel serves as CEO, managing operations and partnerships. The foundation has raised over $10 million in donations (per public record) for SENS research and maintains philanthropic structures including the Methuselah Mouse Prize (Mprize), awarded since 2003 to scientists who achieve lifespan extension in mice. November 2020: Announced a partnership with the SENS Research Foundation to merge research operations (per the foundation's communiqué, November 2020). The Methuselah Foundation's structural differentiator is its early pivot from pure nonprofit philanthropy to a hybrid model that incubates for-profit entities — funding early-stage longevity science through grants and prize models, then spinning out companies to commercialize breakthroughs. This blended architecture, combined with the SENS framework's specific focus on damage repair over slowing aging, distinguishes it from broader aging research foundations.
General information
Firm type
Nonprofit Foundation
Year founded
2003
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Palo Alto
Corporate office
Palo Alto, CA, United States
Additional offices
San Francisco, CA, United States · Leipzig, Germany · Graz, Austria · Hingham, MA, United States · Schwyz, Switzerland
Principals
Aubrey de Grey
Co-Founder and Chief Science Officer
David Gobel
Co-Founder and CEO
Sector focus
Frequently asked questions
Who founded the Methuselah Foundation and how is it governed?
The Methuselah Foundation was co-founded in 2003 by Aubrey de Grey and David Gobel. De Grey serves as Chief Science Officer, setting the SENS research agenda, while Gobel is CEO, overseeing operations. The organization is a 501(c)(3) nonprofit governed by a board of directors.
What is SENS and how does it guide the foundation's investments?
SENS (Strategies for Engineered Negligible Senescence) is a framework developed by de Grey that classifies age-related damage into seven categories — including mitochondrial mutations, cell loss, and extracellular crosslinks — and proposes repair therapies. The foundation funds research projects aligned with these categories, often through grants or prize competitions.
Does the Methuselah Foundation invest directly in for-profit companies?
Yes, the foundation operates a hybrid model: it makes grants and awards prizes to academic labs, but also spins out or invests in for-profit entities such as AgeX Therapeutics and the Longevity Fund. These vehicles are intended to commercialize SENS-based therapies and generate returns that can be recycled into further research.
What is the Methuselah Mouse Prize (Mprize)?
The Mprize, established in 2003, is a monetary award given to researchers who achieve record lifespan extension in mice. It aims to incentivize breakthroughs that are translatable to humans. Prizes are awarded based on peer-reviewed results, with amounts varying by milestone (per public record).
How does the foundation relate to the SENS Research Foundation?
The SENS Research Foundation (SRF) was a separate nonprofit focused on advancing SENS science. In November 2020, the Methuselah Foundation and SRF agreed to merge their research operations, consolidating efforts under a single entity (per the foundation's communiqué, November 2020). The Methuselah Foundation now coordinates the combined research programs.
What geographic regions does the Methuselah Foundation operate in?
The foundation is headquartered in Palo Alto, California, with offices in San Francisco, Leipzig (Germany), Graz (Austria), Hingham (Massachusetts), and Schwyz (Switzerland). Its research grants and prize programs fund scientists globally, but the majority of funded labs are in the United States and Europe.
Does the foundation accept outside donations, and how are funds deployed?
Yes, the Methuselah Foundation raises donations from individuals and organizations. Public records indicate the organization has raised over $10 million for SENS-related research. Funds are deployed through grants, prizes, and operational support for the nonprofit and its spinouts. Donors receive no equity, but may gain recognition in foundation materials.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on endowments & foundations?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: